

# Justin J Wilkins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5793659/publications.pdf>

Version: 2024-02-01

24  
papers

711  
citations

858243

12  
h-index

721071

23  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1010  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacometrics in tuberculosis: progress and opportunities. <i>International Journal of Antimicrobial Agents</i> , 2022, 60, 106620.	1.1	3
2	Pharmacokinetics and Exposure-Efficacy Relationships of Omalizumab in Patients with Nasal Polyps. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 71, 102080.	1.1	2
3	Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 588-596.	2.3	33
4	The guard changes. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2020, 47, 3-4.	0.8	0
5	Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- $\beta$ 2 and PD-L1. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 566-574.	2.3	15
6	Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types. <i>Advances in Therapy</i> , 2019, 36, 2414-2433.	1.3	12
7	Nonlinear Mixed-Effects Model Development and Simulation Using nlmixr and Related R Open-Source Packages. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 621-633.	1.3	34
8	Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 415-427.	1.3	53
9	Performance of the SAEM and FOCEI Algorithms in the Open-Source, Nonlinear Mixed Effect Modeling Tool nlmixr. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 923-930.	1.3	8
10	Data standards for model-informed drug development: an ISoP initiative. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 659-661.	0.8	4
11	Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1. <i>Journal of Clinical Oncology</i> , 2018, 36, 2566-2566.	0.8	9
12	Open innovation: Towards sharing of data, models and workflows. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S65-S71.	1.9	25
13	A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 267-278.	1.0	10
14	Single-dose Pharmacokinetics and Tolerability of Oral Delta-9-Tetrahydrocannabinol in Patients with Amyotrophic Lateral Sclerosis. <i>Drug Metabolism Letters</i> , 2012, 6, 102-108.	0.5	11
15	Systemic pharmacokinetics of indacaterol, an inhaled once-daily long-acting $\beta$ 2-agonist, in different ethnic populations. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 545-556.	0.3	8
16	Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 51-62.	1.1	90
17	Population Pharmacokinetics of Ethambutol in South African Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4230-4237.	1.4	46
18	Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales. <i>AAPS Journal</i> , 2010, 12, 683-691.	2.2	3

#	ARTICLE	IF	CITATIONS
19	Evaluation of the nonparametric estimation method in nonmem VI: application to real data. Journal of Pharmacokinetics and Pharmacodynamics, 2009, 36, 297-315.	0.8	7
20	Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients, Including a Semimechanistic Model To Describe Variable Absorption. Antimicrobial Agents and Chemotherapy, 2008, 52, 2138-2148.	1.4	129
21	Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. European Journal of Clinical Pharmacology, 2006, 62, 727-735.	0.8	69
22	NONMEMory: A run management tool for NONMEM. Computer Methods and Programs in Biomedicine, 2005, 78, 259-267.	2.6	37
23	Population Pharmacokinetics of Rifapentine and Its Primary Desacetyl Metabolite in South African Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 2005, 49, 4429-4436.	1.4	14
24	Effects of Morphine and Tramadol on Somatic and Visceral Sensory Function and Gastrointestinal Motility after Abdominal Surgery. Anesthesiology, 1999, 91, 639-639.	1.3	89